Enwei Pharmaceutical Co., Ltd. Class A

Enwei Pharmaceutical Co., Ltd. Class A

SSZSE:301331
22.40
CNY
-1.01
(-4.31%)
0.36EPS
58.80P/E
2.25BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A carries a market capitalization of 2.25B, placing it among publicly traded companies globally. Its enterprise value stands at 1.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.25B
Enterprise Value1.97B

Share Statistics

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A has 102.89M shares outstanding.

Shares Outstanding102.89M

Valuation Ratios

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 58.80. The price-to-sales ratio is 2.68, and the price-to-book ratio stands at 2.18.

PE Ratio58.80
PS Ratio2.68
PB Ratio2.18
P/TBV Ratio2.73

Enterprise Valuation

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 45.27 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 45.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.97B versus a market cap of 2.25B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.37
EV / EBITDA45.27
EV / EBIT45.27

Financial Position

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A maintains a current ratio of 4.35, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.70, indicating elevated leverage, while an interest coverage ratio of 21.38 demonstrates strong ability to service its debt obligations.

Current Ratio4.35
Quick Ratio2.44
Debt / Equity19.70
Debt / EBITDA4.66
Interest Coverage21.38

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 552,459.84 in revenue per employee across its workforce of 1,501.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee552,459.84
Employee Count1,501.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A recorded 10.56M in income tax expense. That works out to an effective tax rate of 21.85, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 48.35M, leaving 37.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax10.56M
Effective Tax Rate21.85

Stock Price Statistics

CNY

As of the close on November 17, 2026, Enwei Pharmaceutical Co., Ltd. Class A's stock has declined approximately 28.80% over the past 52 weeks. The 50-day moving average sits at 21.80, while the 200-day moving average is 24.24.

52-Week Price Change-28.80%
50-Day Moving Average21.80
200-Day Moving Average24.24

Income Statement

CNY

Over the twelve months ended September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A generated 829.24M in revenue and converted that into 37.78M in net income, yielding earnings per share of 0.36. EBITDA reached 43.49M, while operating income came in at 48.15M.

Revenue829.24M
Gross Profit420.16M
Operating Income48.15M
Pretax Income48.35M
Net Income37.78M
EBITDA43.49M
EBIT43.49M
Earnings Per Share (EPS)0.36

Balance Sheet

CNY

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A holds 481.09M in cash and equivalents against 202.72M in total debt, resulting in a net debt position of -148.15M. Total book value stands at 1.03B, with working capital of 660.59M providing operational flexibility.

Cash & Cash Equivalents481.09M
Total Debt202.72M
Net Debt-148.15M
Equity (Book Value)1.03B
Book Value Per Share10.00
Working Capital660.59M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-51.69M

Margins

Over the twelve months ended September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A posted a gross margin of 50.67, reflecting its pricing power and cost economics. The operating margin of 5.81 and net profit margin of 4.56 provide insight into operational efficiency.

Gross Margin50.67
Operating Margin5.81
Pretax Margin5.83
Profit Margin4.56
EBITDA Margin5.24

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A paid dividends of 1.05 per share. The dividend payout ratio of 283.05 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.92, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Enwei Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share1.05
Payout Ratio283.05
Shareholder Yield3.92

Stock Splits

Enwei Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 23, 2024 with a 25:37 split ratio.

Last Split Date5/23/2024
Split Ratio25:37

Scores

As of September 30, 2026, Enwei Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 5.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.06